Source: Nanomedicine. Unidades: ICB, FCF
Subjects: FARMACOLOGIA, NEOPLASIAS MAMÁRIAS, NANOTECNOLOGIA, ANTINEOPLÁSICOS, QUIMIOTERÁPICOS, MELANOMA, FARMACOS, MEDICAMENTO
ABNT
APOLINÁRIO, Alexsandra Conceição et al. Exploring the benefits of nanotechnology for cancer drugs in different stages of the drug development pipeline. Nanomedicine, v. 15, n. 26, p. 2539–2542, 2020Tradução . . Disponível em: https://doi.org/10.2217/nnm-2020-0290. Acesso em: 13 nov. 2024.APA
Apolinário, A. C., Hirata, A. S., Miguel, R. dos A., Costa-Lotufo, L. V., Pessoa Junior, A., Clair, J. J. L., et al. (2020). Exploring the benefits of nanotechnology for cancer drugs in different stages of the drug development pipeline. Nanomedicine, 15( 26), 2539–2542. doi:10.2217/nnm-2020-0290NLM
Apolinário AC, Hirata AS, Miguel R dos A, Costa-Lotufo LV, Pessoa Junior A, Clair JJL, Fenical W, Lopes LB. Exploring the benefits of nanotechnology for cancer drugs in different stages of the drug development pipeline [Internet]. Nanomedicine. 2020 ; 15( 26): 2539–2542.[citado 2024 nov. 13 ] Available from: https://doi.org/10.2217/nnm-2020-0290Vancouver
Apolinário AC, Hirata AS, Miguel R dos A, Costa-Lotufo LV, Pessoa Junior A, Clair JJL, Fenical W, Lopes LB. Exploring the benefits of nanotechnology for cancer drugs in different stages of the drug development pipeline [Internet]. Nanomedicine. 2020 ; 15( 26): 2539–2542.[citado 2024 nov. 13 ] Available from: https://doi.org/10.2217/nnm-2020-0290